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article under the CC BY-NC-ND licenseAbstract Objective: The prevalence of benign prostatic hyperplasia (BPH) rapidly increases
after the 4th decade of life. The combination of tamsulosin and dutasteride is a well estab-
lished therapy for BPH of 40 g. Non-invasive urodynamic parameters can predict the outcome
of medical therapy in patients with BPH. We aimed to correlate these parameters with treat-
ment responses in BPH patients under medical management.
Methods: A prospective study was conducted in the Department of Urology in our hospital from
May 2014 to April 2015. A total of 100 patients with BPH 40 g who fulfilled our inclusion
criteria were included. Treatment responses were determined by the International Prostate
Symptom Score (IPSS) and uroflowmetry. Transabdominal ultrasonography with Doppler was
performed to measure prostate volume, intravesical prostatic protrusion (IPP), detrusor wall
thickness (DWT), the prostatic capsular artery resistive index (RI) and prostatic urethral angle
(PUA) before and 3 months after combination therapy of tamsulosin and dutasteride. Treat-
ment responses were correlated with non-invasive urodynamic parameters.
Results: The IPSS, uroflow, age, prostate volume, RI, IPP, DWT and PUA were correlated before
and after treatment. Of the 100 patients, 70 (70%) showed significant improvement and 30
(30%) showed no improvement with therapy.
Conclusion: Ultrasound bladder parameters are useful tools for measuring the treatment
response in BPH patients. Our study shows that RI and DWT significantly correlate with the
treatment response in BPH patients. More importantly, pretreatment values of increased IPP
and PUA determines the non-improvement of symptoms in BPH patients. Our study suggests
the importance of transabdominal ultrasonography (KUBeP) with Doppler for evaluating treat-
ment responses to medical management.om (R. Thekumpadam Puthenveetil).
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creativecommons.org/licenses/by-nc-nd/4.0/).Figure 1 Representative ultrasound image that was used for
measurement of the resistive index (RI) of capsular artery of
the prostate RIZðPSVeEDVÞ=PSV; PSV, peak systolic velocity;1. Introduction
The prevalence of benign prostatic hyperplasia (BPH) in-
creases rapidly after the 4th decade of life, reaching nearly
100% in the 9th decade [1]. The American Urological Asso-
ciation (AUA) symptom score index is widely used and is
validated as an important means of assessing men with
lower urinary tract symptoms (LUTS) [1]. The original AUA
symptom score is based on answers to seven questions
concerning frequency, nocturia, a weak urinary stream,
hesitancy, intermittency, incomplete bladder emptying,
and urgency. The International Prostate Symptom Score
(IPSS) includes these seven questions, as well as a global
quality-of-life question. The total symptom score ranges
from 0 to 35, with scores of 0e7, 8e19, and 20e35, indi-
cating mild, moderate, and severe LUTS, respectively. The
IPSS is a helpful tool for the clinical management of men
with LUTS and in research studies regarding medical and
surgical treatment of men with voiding dysfunction due to
BPH. Uroflowmetry is recommended by the AUA during
evaluation of a patient with BPH. Uroflowmetry is the best
non-invasive urodynamic test to detect lower urinary tract
obstruction [2]. The combination of tamsulosin and dutas-
teride is a well established therapy for BPH greater than
40 g. Non-invasive urodynamic parameters such as intra-
vesical prostatic protrusion (IPP), detrusor wall thickness
(DWT), the prostatic capsular artery resistive index (RI) and
prostatic urethral angle (PUA) can predict the outcome of
medical therapy in patients with BPH. This study is aimed to
correlate these non-invasive urodynamic parameters with
treatment responses in patients with BPH under medical
management.
2. Materials and methods
We conducted a prospective study in the Department of
Urology in our hospital from May 2014 to April 2015.
Informed consent was taken from the subjects. The inclu-
sion criteria of the patients were an IPSS >15, prostate
weight 40 g, uroflowmetry <15 mL/s, serum prostate
specific antigen (PSA) levels <4 ng/mL. Exclusion criteria
were other causes of LUTS, such as neurogenic bladder,
stricture urethra, urinary tract infection, serum PSA levels
>4 ng/mL, prostate weight <40 g and serum creatinine
>1.5 mg/dL. A total of 103 patients with BPH greater than
40 g who fulfilled our inclusion criteria were included in the
study. A thorough clinical evaluation and laboratory and
radiological investigations were performed in all of the
patients. Of the 103 patients, three patients were lost to
follow up and were excluded from the study.
Treatment responses were determined by the IPSS and
uroflowmetry. Transabdominal ultrasonography (KUBeP)
with Doppler was performed to measure the prostateweight, prostatic capsular artery RI, DWT, PUA and IPP at
the time of starting the combination therapy. The RI of the
capsular artery of the prostate was calculated as (peak
systolic velocity e end diastolic velocity)/peak systolic
velocity, measured by ultrasound Doppler (Fig. 1). A cut-off
value of 0.69 was considered abnormal in our study popu-
lation. DWT was the thickness of the hypoechoic muscle
between two hyperechoic layers corresponding to the
serosa and mucosa. Three measurements of the anterior
bladder wall were taken at a filling volume of 250 mL and
the average of these was used to measure the DWT (Fig. 2).
A cut-off value of more than 2.9 mm was considered
abnormal in our study population. The PUA was the angle
formed by the proximal prostatic urethra with the distal
prostatic urethra in sagital section of ultrasonography at a
bladder volume of 250 mL (Fig. 3). Patients with a PUA 35
were considered abnormal. IPP was measured by the length
from the tip of the protruding prostate into the bladder, to
the bladder circumference at the base of the prostate
(Fig. 4). A cut-off value of more than 5 mm was considered
abnormal in our study population.
Combination therapy with tamsulosin 0.4 mg and
dutasteride 0.5 mg daily was started in all of the patients
for three months. After 3 months of combination therapy,
we repeated KUB-P with Doppler to measure the above-
mentioned parameters. Treatment responses that were
determined by the IPSS and uroflowmetry were correlated
with the non-invasive urodynamic parameters. Correlation
of the prognostic variables was analyzed with the Z-test.
p < 0.05 was considered significant.EDV, end-diastolic velocity.
Figure 2 Representative ultrasound image used for mea-
surement of the detrusor wall thickness (DWT). At least three
measurements of the anterior bladder wall were taken at a
filling volume of 250 mL. The thickness of the hypoechoic
muscle between two hyperechoic layers corresponding to the
serosa and mucosa was measured.
Figure 4 Representative ultrasound image that was used for
measurement of the intravesical prostatic protrusion (IPP),
which was defined as the length measured from the tip of the
protruding prostate into the bladder to the bladder circum-
ference at the base of the prostate.
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The total numbers of patients in our study was 100. Their
age ranged 58e70 years with a mean age of 63.5  6.0
years. The prostate weight ranged 41e57 g with a mean
weight of 51.2  5.0 g. The uroflow of patients ranged
7e11 mL/s with a mean uroflow of 8.6  2.0 mL/s. The IPSS
of the patients ranged 16e24 with a mean IPSS of 20  4.
Table 1 shows the mean values of RI, IPP, DW and PUA
determined by KUB-P.
Patients were put on combination therapy with tamsu-
losin (0.4 mg) and dutasteride (0.5 mg) daily for 3 months.
The IPSS score and uroflowmetry were done in all patients
after 3 months to measure the treatment response. Trans-
abdominal ultrasonography was done to measure prostate
volume, RI, IPP, DWT and PUA.Figure 3 Representative ultrasound image that was used for
measurement of the prostatic urethral angle (PUA), which was
defined as the angle formed by the proximal prostatic urethra
and the distal prostatic urethra.Out of 100 patients, 70 (70%) patients significantly
symptomatically improved (p < 0.0001) and 30 (30%) pa-
tients did not improve with 3 months of combination
therapy. The mean values of uroflow and IPSS of these 70
patients were significantly improved after treatment
(p < 0.0001). The mean values of RI and DWT of these 70
patients were significantly different after treatment
compared with that of before treatment (p < 0.0001 and
p Z 0.0256). However, mean values of IPP and PUA of
these 70 patients were not significantly different after
treatment in compared with that of before treatment
(p > 0.9999) (Table 2).
The mean value of uroflow and IPSS of the 30 patients
who did not symptomatically improved were not signifi-
cantly different after treatment which were compared with
before treatment (p Z 0.862 and p Z 0.832). The mean
values of RI, IPP, DWT and PUA of these 30 patients were
also not significantly different after treatment compared
with before treatment (p Z 0.17, p > 0.999, p Z 0.9785
and p > 0.9999, respectively) (Table 2).Table 1 Parameters before treatment (n Z 100).
Parameter Value
Uroflow (mL/s) 8.6  2.0
IPSS 20.0  4.0
RI 0.73  0.11
IPP (mm) 5.2  4.5
DWI (mm) 4.80  1.77
PUA () 36.4  17.5
IPSS, International Prostate Symptom Score; RI, resistive index
of prostatic capsular artery; IPP, intravesical prostatic protru-
sion; DWI, detrusor wall thickness; PUA, prostatic urethral
angle. Data are presented as mean  SD.
Table 2 Parameters in symptomatically improved patients and symptomatically non-improved patients.
Parameter Symptomatically improved patients (n Z 70) Symptomatically non-improved patients (n Z 30)
Before treatment After treatment p-Value Before treatment After treatment p-Value
Uroflow (mL/s) 9.4  2.0 16.9  2.0 <0.0001 10.12  2 11.9  2.0 0.862
IPSS 19.6  4.0 9.2  3.0 <0.0001 19.8  4 16.2  3.0 0.832
RI 0.76  0.06 0.62  0.04 <0.0001 0.65  0.04 0.61  0.04 0.17
IPP (mm) 3.35  2.00 3.34  2.00 >0.9999 8.00  2.00 8.00  2.00 >0.999
DWT (mm) 5.38  1.28 4.15  1.23 0.0256 4.12  1.02 4.11  1.01 0.9785
PUA () 23.6  5.0 23.4  5.0 >0.9999 49.3  5.0 49.2  5.0 >0.9999
IPSS, International Prostate Symptom Score; RI, resistive index of prostatic capsular artery; IPP, intravesical prostatic protrusion; DWI,
detrusor wall thickness; PUA, prostatic urethral angle. Data are presented as mean  SD.
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patients was not significantly different after treatment
in compare with before treatment (52.0  4.5 g vs.
52.1  3.2 g, p > 0.05). The prostate weight of symp-
tomatically non-improved patients was also not signifi-
cantly different after treatment compared with before
treatment (50.0  4.3 g vs. 50.1  3.5 g, p > 0.05).
4. Discussion
The prevalence of BPH is age dependent [3]. BPH usually
begins to develop after the age of 40 years, and its preva-
lence becomes greater than 50% by 60 years, and as high as
100% by 85 years [3]. Despite the high prevalence of BPH,
its pathogenesis is still poorly understood.
BPH is bothersome to patients when it is combined with
LUTS. Urodynamic studies are helpful for assessing men
with bothersome LUTS due to BPH. However, the invasive
nature of urodynamic studies and potential complications
have limited its routine clinical application [4,5]. Several
recent studies have reported the importance of anatomical
factors in evaluating LUTS due to BPH. Transabdominal ul-
trasonography is a non-invasive study that can be used on
an outpatient basis to evaluate the anatomical structure of
the prostate.
With the advent of power Doppler imaging, the RI of
capsular arteries in patients with LUTS has become a
promising parameter in the evaluation of BPH. The definite
mechanism through which the RI is elevated in BPH is still
unclear [6]. Hyperplastic prostate tissue is thought to push
the capsule out as it grows, thus increasing the intra-
prostatic pressure, as well as the RI. A lower IPSS and peak
flow rate are correlated with a high RI of capsular arteries.
Kojima et al. [7] showed a significant correlation between
the RI and urodynamic parameters obtained in peak flow
rate (Qmax) of uroflowmetry and IPSS in their study. Shinbo
et al. [8] studied the RI as a risk for acute urinary retention
in patients with BPH. They found that the RI was increased
in patients with BPH and was related to the severity of
bladder outlet obstructive symptoms. Kojima et al. [7]
also demonstrated that the RI value of patients with a
normal prostate volume was significantly lower than that
of patients with an enlarged prostate (0.64  0.04 vs.
0.72  0.06; p < 0.0001). They found a cut-off value of
0.69, the RI distinguished patients with and without
bladder outlet obstruction with 78% sensitivity and 86.4%specificity. In the current study, the mean values of the
IPSS and RI in the 70 improved patients decreased. We also
found that the uroflow improved after treatment
compared with before treatment. These findings clearly
indicated that the prostatic capsular artery RI is signifi-
cantly higher in patients with bladder outlet obstruction
due to BPH. Additionally, improvement of the RI of
capsular arteries directly correlated with improvement of
the IPSS and uroflow in patients. Therefore, RI can be used
as an index for measurement of improvement in symptoms
in lower urinary tract obstruction due to BPH.
Measurement of DWT (thickness of the hypoechoic
muscle between two hyperechoic layers corresponding to
the serosa and mucosa) by ultrasound is reliable, where at
least three measurements of the anterior bladder wall are
taken at a filling volume of 250 mL. Using a cut-off value
>2.9 mm in men, DWT is considered the best diagnostic tool
to measure detrusor hypertrophy [9]. In symptomatically
improved patients after 3 months of combination therapy,
the IPPS was improved, DWT was reduced and uroflow was
increased compared with before treatment. In patients
with no symptomatic improvement, after 3 months of
therapy, the IPPS, uroflow and DWT were not significantly
different compared with before treatment. These findings
suggest that a decrease in DWT significantly correlated with
an improvement in the IPSS.
The prostatic urethra is a bent tube, and the clinical
significance of the PUA was recently reported [10,11]. An
increased PUA may be the result of a higher bladder neck in
men who have no lateral or median prostatic lobe
enlargement [11]. Although some urologists suspect that a
higher bladder neck might be due to the presence of BPH,
the clinical significance of PUA is not well understood. The
prostatic urethra runs through the prostate from the base
to the apex, making an anterior angle of 35 at the proximal
part of the verumontanum. This bend divides the urethra
into the proximal and distal portions [12]. By applying fluid
dynamics to the process of urination in the prostatic ure-
thra, Cho et al. [11] suggested that energy loss in the
bending tube in the prostatic urethra could occur during
micturition. They insisted that because of the increased
energy loss resulting from the PUA, this leads to a decrease
in urine velocity, and the urine flow rate is inversely asso-
ciated with the PUA [10]. Ku et al. [13] found that as the
PUA increases, the bladder outlet obstruction index in-
creases. Patients with a PUA 35 were more likely to have
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in 70 patients who symptomatically improved after combi-
nation therapy as mentioned above, the IPSS improved,
while uroflow was increased after treatment but there was
little change in the PUA. However, in the 30 patients who
did not improve symptomatically, the mean values of the
IPSS, uroflow and PUA were unchanged after treatment
compared with before treatment. These results indicated
that pretreatment values of a large PUA were significantly
correlated with non-improvement of symptoms in patients
with BPH.
IPP is a morphological change by which the prostate
protrudes into the bladder during the process of prostatic
enlargement. It is induced by enlargement of the median
lobe, which leads to a ball-valve type of bladder outlet
obstruction. As a result, there is abnormal movement of the
bladder leading to inhibition of the funnel effect of the
bladder neck at urination [14,15]. Chia et al. [16] described
that strong bladder contractions open the channel between
the lateral lobes, but accelerate the ball-valve effect by
IPP. This induces more bladder outlet obstruction than with
enlargement of the lateral lobe alone without IPP. In our
study, in 70 patients who symptomatically improved after
combination therapy while IPSS improved and uroflow
increased after treatment, there was little change in IPP.
However, in the 30 patients who did not improve symp-
tomatically, the mean values of the IPSS, uroflow and PUA
were unchanged after treatment compared with before
treatment. These results showed that a higher pretreat-
ment IPP was significantly correlated with no improvement
of symptoms in patients with BPH.5. Conclusion
Ultrasound bladder parameters, such as IPP, DWT, the RI,
and the PUA are considered as potential non-invasive
clinical tools for baseline assessment of patients with
bladder outlet obstruction. Our study shows that the RI
and DWT are significantly correlated with the treatment
response in patients with BPH. More importantly, pre-
treatment values of high IPP and PUA do not affect a lack
of improvement in symptoms in patients with BPH. This
preliminary prospective study indicates that ultrasound
bladder parameters are useful tools for measuring the
treatment response in patients with BPH. A long-term
study with a large series is required to confirm our
findings.Conflicts of interest
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